The long non‐coding RNA LOC285758 promotes invasion of acute myeloid leukemia cells by down‐regulating miR‐204‐5p

Xue, Fangzheng; Che, Haiyan

doi:10.1002/2211-5463.12814

Cited by 9 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2c, d ). These two miRNAs were both negative regulators of AML development and inhibited the growth of AML cells 38 , 39 . The findings indicated that the CD27-AS1/miR-224-5p axis may be one of the ways that CD27-AS1 regulates the growth of AML cells.…”

Section: Discussionmentioning

confidence: 99%

LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

et al. 2021

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a hematological malignancy with a low cure rate, especially in the elderly. Previous studies have shown that long non-coding RNA (lncRNA) may be an important factor in the pathogenesis of hematological malignancies, including acute myeloid leukemia (AML). However, the biological roles and clinical significances of most lncRNAs in AML are not fully understood. LncRNA CD27 Antisense RNA 1 (CD27-AS1), as a member of lncRNA family, has rare reports on its function. In present study, we found that the expression of CD27-AS1 examined by quantitative real-time PCR was markedly increased in the AML patients (N = 40) compared with healthy volunteers (N = 40). The overall survival time was significantly shorter in patients with higher CD27-AS1 expression than that in patients with lower CD27-AS1 (P < 0.01). Furthermore, downregulation of CD27-AS1 in AML cells suppressed proliferative ability, arrested cell cycle in G0/G1 phase, and induced apoptosis. However, CD27-AS1 overexpression further enhanced the malignant phenotype of AML cells. Additionally, CD27-AS1 was proved to increase PBX3 expression through sponging miR-224-5p. CD27-AS1 knockdown blocked the MAPK signaling through PBX3 silencing and further inhibited the cell growth of AML cells. Taken together, we demonstrate that CD27-AS1 may be a potential prognostic biomarker of AML, and our finding also provides a new insight for non-coding RNA-based therapeutic intervention of AML.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

et al. 2021

View full text Add to dashboard Cite

show abstract

“…LINC01268 has been recently described as being upregulated in AML samples [ 52 , 53 ]. In a first work LINC01268 has been described as acting as competing endogenous RNA (ceRNA) via sponging the onco-suppressor miR-217 which in turns inhibits at the post-transcriptional level SOS1 mRNA.…”

Section: Discussionmentioning

confidence: 99%

“…An upregulation of LINC01268 (therein referred as LOC285758 ) was described also to induce invasion and viability in AML cells by directly sponging miR-204, which inhibited N-Cadherin and TWIST -1 and increased E-Cadherin [ 53 ]. A downregulation of miR-204 in AML was also described by the work of Butrym et al, where decreased serum level of miR-204 have been correlated with a poor prognosis of AML [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis

Fantini

Rontauroli

Sartini

et al. 2021

Cancers

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been recently described as key mediators in the development of hematological malignancies. In the last years, circulating lncRNAs have been proposed as a new class of non-invasive biomarkers for cancer diagnosis and prognosis and to predict treatment response. The present study is aimed to investigate the potential of circulating lncRNAs as non-invasive prognostic biomarkers in myelofibrosis (MF), the most severe among Philadelphia-negative myeloproliferative neoplasms. We detected increased levels of seven circulating lncRNAs in plasma samples of MF patients (n = 143), compared to healthy controls (n = 65). Among these, high levels of LINC01268, MALAT1 or GAS5 correlate with detrimental clinical variables, such as high count of leukocytes and CD34+ cells, severe grade of bone marrow fibrosis and presence of splenomegaly. Strikingly, high plasma levels of LINC01268 (p = 0.0018), GAS5 (p = 0.0008) or MALAT1 (p = 0.0348) are also associated with a poor overall-survival while high levels of LINC01268 correlate with a shorter leukemia-free-survival. Finally, multivariate analysis demonstrated that the plasma level of LINC01268 is an independent prognostic variable, suggesting that, if confirmed in future in an independent patients’ cohort, it could be used for further studies to design an updated classification model for MF patients.

show abstract

“…MiR-204 expression in AML patients was decreased and was associated with shorter patient survival. Higher expression of this miR was observed in patients after induction therapy and was correlated with complete remission [ 55 ], and its targeting promotes the viability and invasion of AML cells [ 56 ]. Wang et al demonstrated that overexpression of these miRNAs potentiates the sensitivity of AML cells to arsenic trioxide [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, recent work showed that in breast cancer, miR-204 regulated the expression of key cytokines in tumor cells and reprogrammed immune cells by shifting myeloid and lymphocyte populations, suggesting that this miRNA suppresses tumor metastasis and remodeling the immune microenvironment [ 58 ]. MiR-518b was also reported to function as a tumor suppressor in glioblastoma [ 56 ], esophageal and squamous cell carcinoma [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

Agha

Rouas

Najar

et al. 2020

IJMS

View full text Add to dashboard Cite

Background: In addition to their roles in different biological processes, microRNAs in the tumor microenvironment appear to be potential diagnostic and prognostic biomarkers for various malignant diseases, including acute myeloid leukemia (AML). To date, no screening of circulating miRNAs has been carried out in the bone marrow compartment of AML. Accordingly, we investigated the circulating miRNA profile in AML bone marrow at diagnosis (AMLD) and first complete remission post treatment (AMLPT) in comparison to healthy donors (HD). Methods: Circulating miRNAs were isolated from AML bone marrow aspirations, and a low-density TaqMan miRNA array was performed to identify deregulated miRNAs followed by quantitative RT-PCR to validate the results. Bioinformatic analysis was conducted to evaluate the diagnostic and prognostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s). Results: We found several deregulated miRNAs between the AMLD vs. HD vs. AMLPT groups, which were involved in tumor progression and immune suppression pathways. We also identified significant diagnostic and prognostic signatures with the ability to predict AML patient treatment response. Conclusions: This study provides a possible role of enriched circulating bone marrow miRNAs in the initiation and progression of AML and highlights new markers for prognosis and treatment monitoring.

show abstract

The long non‐coding RNA LOC285758 promotes invasion of acute myeloid leukemia cells by down‐regulating miR‐204‐5p

Cited by 9 publications

References 29 publications

LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

Contact Info

Product

Resources

About